Intralipid

Soya Oil, Purified, the active ingredient in Intralipid, is an intravenous lipid emulsion presented as a liquid emulsion for intravenous use. It supplies calories and essential fatty acids to patients who cannot receive enteral feeding, supporting nutritional needs and preventing essential fatty acid deficiency.

GNH USA supplies Intralipid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use. Global logistics ensure timely delivery to acute care facilities across Europe and beyond.

Intralipid is an intravenous lipid emulsion used in parenteral nutrition and related clinical situations. - Parenteral nutrition for patients unable to receive enteral feeding: provides essential calories and fatty acids to maintain energy balance. - Essential fatty acid deficiency prevention and treatment: restores linoleic and alpha‑linolenic acid levels in at‑risk individuals. - Solvent for certain intravenous drug formulations: serves as a compatible lipid carrier for lipophilic medications.

Intralipid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypertriglyceridemia: transient rise in serum triglycerides that may require monitoring. - Fever and chills: mild temperature increase and shivering often occurring at infusion start. - Nausea or vomiting: occasional gastrointestinal upset during or shortly after administration. - Infusion site reactions: erythema, pain, swelling or phlebitis at the catheter entry point.

Serious or Rare Side Effects: - Fat overload syndrome: excessive lipid load causing respiratory distress, hepatic enlargement and coagulopathy. - Pancreatitis: acute inflammation of the pancreas linked to markedly elevated triglyceride concentrations. - Anaphylaxis or severe allergic reaction: rapid onset of urticaria, bronchospasm, hypotension and possible shock. - Hepatic dysfunction: significant rise in liver enzymes or fatty liver changes with prolonged therapy.

When using Intralipid, specific precautions help minimize risks and ensure safe administration. - Monitor triglyceride levels: check serum triglycerides regularly to avoid fat overload. - Assess lipid tolerance: evaluate for signs of hypersensitivity before each infusion. - Use aseptic technique: prepare and administer under sterile conditions to prevent contamination. - Avoid in severe hyperlipidemia: contraindicated for patients with markedly elevated baseline lipids. - Adjust in hepatic impairment: reduce dosage or frequency in patients with liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intralipid can interact with other medications, influencing lipid metabolism or infusion compatibility.

Major Interactions (Avoid): - Concurrent lipid emulsions: co‑administration with other IV lipid products may cause fat overload. - Propofol infusion: both are lipid‑based, increasing risk of hypertriglyceridemia. - Heparin therapy: enhances lipolysis and may exacerbate triglyceride elevation. - Certain antibiotics (e.g., ceftriaxone): can precipitate when mixed with lipid emulsions.

Moderate Interactions (Monitor Closely): - Warfarin: lipid load may alter INR, requiring closer coagulation monitoring. - Corticosteroids: both increase serum triglycerides, necessitating periodic lipid checks. - Diuretics: electrolyte shifts may affect lipid metabolism during therapy. - Other parenteral nutrition components: ensure compatible osmolarity and pH to prevent precipitation.